KA/EN
Register
Medicines reference
Search
Search
Product

Clopi-Denk

Favourites

Clopidogrel · Denk Pharma / Artesan Pharma

1 form: coated tablet. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
75 mg, Coated tablet · Cat Cat 18.75 mg per animal
For selected cardiogenic ATE risk and secondary prevention. This equals one quarter of the nominal 75 mg strength, but Clopi-Denk is unscored and equal quarter-dose accuracy is not validated; prescribe a dose-accurate pharmacy-prepared presentation rather than a visual quarter.
 · q24h with food		 q24h with food Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
In the register: კლოპი-დენკ 75
№ რ-038001
Verified on: 15 Oct 2026
75 mg, Coated tablet · Cat Cat 75 mg per animal
ACVIM low-evidence loading step followed by 18.75 mg q24h. The intact Clopi-Denk tablet matches 75 mg, but loading does not replace analgesia, anticoagulation and management of concurrent CHF or tissue injury.
 · once after acute ATE when PO tolerated		 once after acute ATE when PO tolerated Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
In the register: კლოპი-დენკ 75
№ რ-038001
Verified on: 15 Oct 2026
75 mg, Coated tablet · Dog Dog 1.1–3 mg/kg
Prevention of arterial thromboembolism in a dog with a defined indication. Evidence does not support clopidogrel monotherapy for venous thrombosis. A whole 75 mg tablet supplies this range only at approximately 25–68 kg; use a dose-accurate alternative outside that fit because this exact tablet is not validated for subdivision.
 · once daily		 once daily Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
In the register: კლოპი-დენკ 75
№ რ-038001
Verified on: 15 Oct 2026
75 mg, Coated tablet · Dog Dog 4–10 mg/kg
Optional canine loading range, not a routine extra dose. Weigh GI/bleeding risk and the exact indication; this unscored 75 mg tablet may not provide the calculated dose accurately.
 · once when rapid exposure is required		 once when rapid exposure is required Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
In the register: კლოპი-დენკ 75
№ რ-038001
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Clopi-Denk 75 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Oral prevention of arterial thromboembolism in dogs with a defined thrombotic indication; not routine broad prophylaxis or sole therapy for venous thrombosis
6.3/10
Situational / acceptable
vetman assessment

Clopi-Denk

75 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Oral prevention of arterial thromboembolism in dogs with a defined thrombotic indication; not routine broad prophylaxis or sole therapy for venous thrombosis · By mouth
Care settingVeterinarian-directed hospital or home treatment after defining arterial thrombotic risk, selecting an accurate weight-based dose and reviewing bleeding risk and concurrent antithrombotics.
vetman score 6.3/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038001 · Verified on 15 Oct 2026 Off-label use

A consensus-supported canine arterial antiplatelet option, but clinical-outcome evidence is limited and the unscored 75 mg tablet fits a whole-unit maintenance dose only for a restricted weight range; many prescriptions need a dose-accurate prepared form.

Regulatory and scientific credibility6.5/10

Exact identity, current Georgian human authorisation and an official exact leaflet are traceable, with independent veterinary consensus and species evidence; there is no veterinary authorisation or exact-product target-animal equivalence/outcome dossier.

Clinical efficacy6.5/10

CURATIVE supports clopidogrel for canine ATE prevention and canine PD/PK studies show platelet inhibition, but clinical outcome evidence is sparse and neither VTE monotherapy nor indiscriminate prophylaxis is established.

Safety and tolerability6.5/10

Exact-label bleeding risks and canine platelet effects are characterised, but small studies show variable or excessive response in some dogs and clinical safety is indication-, dose- and polytherapy-dependent.

Clinical practicality5.0/10

Once-daily oral use and an intact tablet are workable for some medium/large dogs, but weight-based dosing often needs a non-whole dose and this exact unscored tablet is not validated for subdivision or crushing.

Full-course cost-effectiveness-

A current Georgian pack listing exists, but dose-accurate preparation cost, patient-specific duration and comparable alternative cost were not verified together; price is excluded.

Important safety and use flags

  • Human medicine: Georgian registration is for people and does not establish veterinary authorisation. Dog and cat use is off-label by species and indication.
  • Clopi-Denk 75 is a round unscored film-coated tablet. Do not present a visual quarter as a validated 18.75 mg dose or assume crushing preserves dose accuracy; use a pharmacy-prepared dose-accurate form when a whole tablet is not prescribed.
  • Canine recommendation covers prevention of arterial thromboembolism in selected dogs. It does not establish clopidogrel alone for venous thrombosis or routine prophylaxis without a defined risk.
  • Contraindicated with clopidogrel/excipient hypersensitivity, active bleeding or severe liver disease. A bleeding-prone disorder is a high-risk precaution requiring an individual plan, not an automatic exact-label contraindication. Investigate unexplained anaemia, melaena, haematuria, bruising, prolonged bleeding or neurologic deterioration promptly.
  • Before surgery, dentistry or an invasive procedure, make an indication-specific interruption plan; do not stop chronic antithrombotic treatment automatically or continue it without reviewing haemorrhage risk.
  • Review anticoagulants, heparins, aspirin and other antiplatelets, NSAIDs and SSRIs. Combination treatment may be intentional, but additive bleeding risk requires a documented benefit-risk decision and monitoring.
  • Review omeprazole/esomeprazole and other CYP-modifying medicines listed by the exact label; choose gastroprotection and co-medication deliberately rather than assuming all proton-pump inhibitors are interchangeable.
  • Canine platelet response varies and can be excessive. Clinical bleeding surveillance remains necessary even when a standard mg/kg dose is used.
  • Clopidogrel response is variable. Recurrence does not automatically prove non-adherence, and an ex-vivo assay result is not a substitute for reassessing indication, dose preparation, interactions and concurrent disease.
  • Exact-product safety in pregnancy, lactation, juveniles and severe renal/hepatic disease is not established. Use only after an individual benefit-risk assessment.
Assessment sources
  1. Clopi-Denk 75 PIL2020
  2. GE Clopi-Denk 75 audit2026
  3. CURATIVE small animal2019
  4. Canine clopidogrel PD/PK2010
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral reduction of cardiogenic arterial-thromboembolism risk and secondary prevention in selected cats, including the acute loading-to-maintenance context
6.8/10
Situational / acceptable
vetman assessment

Clopi-Denk

75 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Oral reduction of cardiogenic arterial-thromboembolism risk and secondary prevention in selected cats, including the acute loading-to-maintenance context · By mouth
Care settingVeterinarian-directed hospital initiation after acute ATE or monitored home prevention after risk assessment, with a dose-accurate maintenance presentation and bleeding/polytherapy review.
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-038001 · Verified on 15 Oct 2026 Off-label use

Strong feline clopidogrel evidence, but this exact 75 mg unscored tablet is a poor maintenance-dose presentation: retain the intact loading role and use a dose-accurate 18.75 mg form for chronic treatment.

Regulatory and scientific credibility6.5/10

Exact identity, current Georgian human authorisation and an official exact leaflet are traceable, with independent veterinary consensus and species evidence; there is no veterinary authorisation or exact-product target-animal equivalence/outcome dossier.

Clinical efficacy8.5/10

FAT CAT provides relevant randomised outcome evidence and ACVIM strongly supports secondary prevention; primary prevention is not directly studied, loading evidence is lower and pharmacodynamic nonresponse occurs in some cats.

Safety and tolerability7.5/10

FAT CAT found chronic treatment well tolerated and feline use is extensive, but bleeding, salivation/retching/vomiting, response variability, surgery and additive antithrombotic effects remain clinically important.

Clinical practicality3.5/10

Once-daily oral treatment is simple and one intact tablet fits the 75 mg loading step, but chronic 18.75 mg requires one quarter of an unscored film-coated tablet with no validated equal-subdivision accuracy; a dose-accurate preparation is needed.

Full-course cost-effectiveness-

A current Georgian pack listing exists, but dose-accurate preparation cost, patient-specific duration and comparable alternative cost were not verified together; price is excluded.

Important safety and use flags

  • Human medicine: Georgian registration is for people and does not establish veterinary authorisation. Dog and cat use is off-label by species and indication.
  • Clopi-Denk 75 is a round unscored film-coated tablet. Do not present a visual quarter as a validated 18.75 mg dose or assume crushing preserves dose accuracy; use a pharmacy-prepared dose-accurate form when a whole tablet is not prescribed.
  • Feline evidence is strongest for secondary prevention after cardiogenic ATE. Primary prevention is risk-selected and the 75 mg acute loading recommendation has lower evidence than 18.75 mg maintenance.
  • Contraindicated with clopidogrel/excipient hypersensitivity, active bleeding or severe liver disease. A bleeding-prone disorder is a high-risk precaution requiring an individual plan, not an automatic exact-label contraindication. Investigate unexplained anaemia, melaena, haematuria, bruising, prolonged bleeding or neurologic deterioration promptly.
  • Before surgery, dentistry or an invasive procedure, make an indication-specific interruption plan; do not stop chronic antithrombotic treatment automatically or continue it without reviewing haemorrhage risk.
  • Review anticoagulants, heparins, aspirin and other antiplatelets, NSAIDs and SSRIs. Combination treatment may be intentional, but additive bleeding risk requires a documented benefit-risk decision and monitoring.
  • Review omeprazole/esomeprazole and other CYP-modifying medicines listed by the exact label; choose gastroprotection and co-medication deliberately rather than assuming all proton-pump inhibitors are interchangeable.
  • Some cats salivate, retch or vomit. An empty gelatin capsule followed by water may improve tolerability, but it does not solve inaccurate tablet quartering.
  • Clopidogrel response is variable. Recurrence does not automatically prove non-adherence, and an ex-vivo assay result is not a substitute for reassessing indication, dose preparation, interactions and concurrent disease.
  • Exact-product safety in pregnancy, lactation, juveniles and severe renal/hepatic disease is not established. Use only after an individual benefit-risk assessment.
Assessment sources
  1. Clopi-Denk 75 PIL2020
  2. GE Clopi-Denk 75 audit2026
  3. ACVIM feline cardiomyopathy2020
  4. FAT CAT trial2015
  5. Feline generic pilot2019
  6. Feline response study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Clopidogrel75 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Denk Pharma / Artesan Pharma · Germany
Registration
Georgia Yes, human
In force until 02 May 2028
Human (Ministry of Health, RAMA)
In the register: კლოპი-დენკ 75
№ რ-038001
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Veterinary use is off-label. Cat: 18.75 mg/cat PO q24h with food for selected cardiogenic ATE risk/secondary prevention; after acute ATE, ACVIM recommends 75 mg PO once when oral medication is tolerated, then 18.75 mg q24h. Dog: 1.1–3 mg/kg PO q24h for prevention of arterial thromboembolism; a 4–10 mg/kg one-time loading dose may be considered. The exact tablet is round, film-coated and unscored: equal quartering and crushing are not validated. Use a dose-accurate pharmacy-prepared presentation whenever the prescribed dose is not a whole tablet.
DoseSpeciesWeightRouteFrequencySource
18.75 mg per animal
For selected cardiogenic ATE risk and secondary prevention. This equals one quarter of the nominal 75 mg strength, but Clopi-Denk is unscored and equal quarter-dose accuracy is not validated; prescribe a dose-accurate pharmacy-prepared presentation rather than a visual quarter.
 Cat Any weight By mouth q24h with food
ACVIM feline cardiomyopathy
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats
Journal of Veterinary Internal Medicine, 2020
75 mg per animal
ACVIM low-evidence loading step followed by 18.75 mg q24h. The intact Clopi-Denk tablet matches 75 mg, but loading does not replace analgesia, anticoagulation and management of concurrent CHF or tissue injury.
 Cat Any weight By mouth once after acute ATE when PO tolerated
ACVIM feline cardiomyopathy
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats
Journal of Veterinary Internal Medicine, 2020
1.1–3 mg/kg
Prevention of arterial thromboembolism in a dog with a defined indication. Evidence does not support clopidogrel monotherapy for venous thrombosis. A whole 75 mg tablet supplies this range only at approximately 25–68 kg; use a dose-accurate alternative outside that fit because this exact tablet is not validated for subdivision.
 Dog Any weight By mouth once daily
CURATIVE small animal
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
American College of Veterinary Emergency and Critical Care consensus on the rational use of antithrombotics in veterinary critical care: small animal
Journal of Veterinary Emergency and Critical Care, 2019
4–10 mg/kg
Optional canine loading range, not a routine extra dose. Weigh GI/bleeding risk and the exact indication; this unscored 75 mg tablet may not provide the calculated dose accurately.
 Dog Any weight By mouth once when rapid exposure is required
CURATIVE small animal
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
American College of Veterinary Emergency and Critical Care consensus on the rational use of antithrombotics in veterinary critical care: small animal
Journal of Veterinary Emergency and Critical Care, 2019

Known Contraindications

  • Critical
    Use with caution in a bleeding disorder or during existing anticoagulant treatment. Combining an antiplatelet medicine with an anticoagulant is used intentionally in cats and can improve survival, but it increases bleeding risk; adverse events occurred in 11–15% of patients in a systematic review and were predominantly minor bleeding.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (26 more) Hide additional products

Same therapeutic group 26

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗